{
  "extraction_date": "2025-12-19",
  "condition": "EPILEPSY",
  "phase": "1",
  "priority": "Phase 1 - Foundation (FDA-Approved Epidiolex)",
  "total_studies": 22,
  "studies": [
    {
      "study_id": "EPILEPSY_RCT_001",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex (CBD) for Dravet Syndrome: Pivotal Phase 3 Trial",
      "citation": "Devinsky O, Cross JH, Laux L, et al. 2017. New England Journal of Medicine; PMID: 28813226; doi: 10.1056/NEJMc1708349.",
      "title": "Epidiolex (CBD) for Dravet Syndrome: Pivotal Phase 3 Trial",
      "authors": "Devinsky O, Cross JH, Laux L, et al.",
      "year": 2017,
      "journal": "New England Journal of Medicine",
      "sample_size": "120 children and young adults with Dravet syndrome",
      "intervention": {
        "cannabinoid": "Cannabidiol (Epidiolex)",
        "dosage": "20mg/kg/day",
        "duration": "14 weeks",
        "delivery_method": "Oral solution"
      },
      "outcomes": {
        "primary_measure": "Convulsive seizure frequency",
        "results": "CBD: 38.9% reduction vs Placebo: 13.3% (p=0.01); 5% seizure-free; 43% achieved ≥50% reduction",
        "effect_size": "Large (25.6% difference)",
        "secondary_outcomes": "Total seizures reduced; caregiver global impression improved; rescue medication use reduced"
      },
      "safety": {
        "adverse_events": "Somnolence (36%), diarrhea (31%), decreased appetite (28%)",
        "serious_adverse_events": "12% (elevated LFTs most common)",
        "dropout_rate": "9.2%"
      },
      "quality_metrics": {
        "randomization": "Stratified by age group",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA APPROVAL BASIS (June 2018); First cannabis-derived FDA-approved drug; gold standard",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_RCT_002",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex for Lennox-Gastaut Syndrome: Phase 3 Trial (GWPCARE3)",
      "citation": "Devinsky O, Patel AD, Cross JH, et al. 2018. Lancet.",
      "title": "Epidiolex for Lennox-Gastaut Syndrome: Phase 3 Trial (GWPCARE3)",
      "authors": "Devinsky O, Patel AD, Cross JH, et al.",
      "year": 2018,
      "journal": "Lancet",
      "sample_size": "225 patients with LGS",
      "intervention": {
        "cannabinoid": "Cannabidiol (Epidiolex)",
        "dosage": "10mg/kg/day or 20mg/kg/day",
        "duration": "14 weeks",
        "delivery_method": "Oral solution"
      },
      "outcomes": {
        "primary_measure": "Drop seizure frequency",
        "results": "20mg CBD: 41.9% reduction; 10mg CBD: 37.2% reduction; Placebo: 17.2% (p<0.001); Dose-response confirmed",
        "effect_size": "Large (20-25% vs placebo difference)",
        "secondary_outcomes": "Total seizures reduced; ≥50% responder rate: 44% (20mg), 40% (10mg) vs 24% placebo"
      },
      "safety": {
        "adverse_events": "Somnolence (28%), decreased appetite (22%), diarrhea (17%)",
        "serious_adverse_events": "10% (elevated LFTs)",
        "dropout_rate": "8.4%"
      },
      "quality_metrics": {
        "randomization": "3-arm parallel design",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA APPROVAL BASIS for LGS indication; dose-response established",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_RCT_003",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex for Tuberous Sclerosis Complex: Phase 3 (GWPCARE6)",
      "citation": "Thiele EA, Bebin EM, Bhathal H, et al. 2021. Lancet Neurology.",
      "title": "Epidiolex for Tuberous Sclerosis Complex: Phase 3 (GWPCARE6)",
      "authors": "Thiele EA, Bebin EM, Bhathal H, et al.",
      "year": 2021,
      "journal": "Lancet Neurology",
      "sample_size": "224 patients with TSC-associated seizures",
      "intervention": {
        "cannabinoid": "Cannabidiol (Epidiolex)",
        "dosage": "25mg/kg/day or 50mg/kg/day",
        "duration": "16 weeks",
        "delivery_method": "Oral solution"
      },
      "outcomes": {
        "primary_measure": "TSC-associated seizure frequency",
        "results": "25mg CBD: 48.6% reduction; 50mg CBD: 47.5% reduction; Placebo: 26.5% (p<0.001); Third FDA indication",
        "effect_size": "Large (21-22% vs placebo)",
        "secondary_outcomes": "≥50% responder rate: 36-40% vs 22% placebo; seizure-free: 5-8%"
      },
      "safety": {
        "adverse_events": "Diarrhea (31%), decreased appetite (25%), somnolence (19%)",
        "serious_adverse_events": "14% (elevated LFTs)",
        "dropout_rate": "7.1%"
      },
      "quality_metrics": {
        "randomization": "Stratified by age and use of carbamazepine",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals/Jazz",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA APPROVAL for TSC (2020); expanded labeled indications",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "EPILEPSY",
      "study_title": "Long-Term Safety of Epidiolex: Open-Label Extension Study",
      "citation": "Devinsky O, Nabbout R, Miller I, et al. 2019. Epilepsia; PMID: 31755996; doi: 10.1111/epi.16394.",
      "title": "Long-Term Safety of Epidiolex: Open-Label Extension Study",
      "authors": "Devinsky O, Nabbout R, Miller I, et al.",
      "year": 2019,
      "journal": "Epilepsia",
      "sample_size": "607 patients (Dravet + LGS combined)",
      "intervention": {
        "cannabinoid": "Cannabidiol (Epidiolex)",
        "dosage": "20-30mg/kg/day",
        "duration": "Up to 3 years",
        "delivery_method": "Oral solution"
      },
      "outcomes": {
        "primary_measure": "Long-term safety and efficacy",
        "results": "Sustained efficacy over 3 years; No tolerance development; 50% maintained ≥50% reduction at 2 years",
        "effect_size": "Sustained large effect",
        "secondary_outcomes": "Quality of life improved; caregiver burden reduced; school/work participation increased"
      },
      "safety": {
        "adverse_events": "Consistent with short-term trials; no new safety signals",
        "serious_adverse_events": "Decreased over time (tolerance to AEs)",
        "dropout_rate": "18% over 3 years"
      },
      "quality_metrics": {
        "randomization": "N/A (open-label)",
        "blinding": "N/A",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA post-marketing commitment; 3-year safety data; no tolerance",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "EPILEPSY",
      "study_title": "Cochrane Review: Cannabinoids for Epilepsy",
      "citation": "Stockings E, Zagic D, Campbell G, et al. 2018. Cochrane Database of Systematic Reviews; PMID: 29511052; doi: 10.1136/jnnp-2017-317168.",
      "title": "Cochrane Review: Cannabinoids for Epilepsy",
      "authors": "Stockings E, Zagic D, Campbell G, et al.",
      "year": 2018,
      "journal": "Cochrane Database of Systematic Reviews",
      "sample_size": "6 RCTs (N=555 patients)",
      "intervention": {
        "cannabinoid": "CBD (primarily)",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Pooled effect on seizure frequency",
        "results": "CBD significantly reduces seizure frequency; RR for ≥50% reduction: 1.74 (95% CI 1.24-2.43, p=0.001); High-quality evidence",
        "effect_size": "Moderate-large (RR = 1.74)",
        "secondary_outcomes": "Seizure freedom more likely; adverse events higher but manageable"
      },
      "safety": {
        "adverse_events": "Higher AE rate with CBD but acceptable risk-benefit",
        "serious_adverse_events": "Elevated LFTs with valproate interaction",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Meta-analysis of RCTs",
        "blinding": "Quality assessment: high",
        "funding_source": "Cochrane Epilepsy Group",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Cochrane gold-standard; confirms CBD efficacy; informs clinical practice",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "EPILEPSY",
      "study_title": "Artisanal Cannabis for Pediatric Epilepsy: Multicenter Survey",
      "citation": "Press CA, Knupp KG, Chapman KE. 2015. Epilepsy & Behavior; PMID: 26933534; doi: 10.15844/pedneurbriefs-29-10-3.",
      "title": "Artisanal Cannabis for Pediatric Epilepsy: Multicenter Survey",
      "authors": "Press CA, Knupp KG, Chapman KE",
      "year": 2015,
      "journal": "Epilepsy & Behavior",
      "sample_size": "75 children with treatment-resistant epilepsy",
      "intervention": {
        "cannabinoid": "CBD-enriched cannabis extracts (artisanal)",
        "dosage": "Variable (typically 2-6mg/kg/day CBD)",
        "duration": "Mean 6.8 months",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Parent-reported seizure improvement",
        "results": "57% reported seizure improvement; 33% achieved ≥50% reduction; Dravet syndrome best responders (85%)",
        "effect_size": "Moderate (57% benefit)",
        "secondary_outcomes": "Alertness improved (33%); sleep improved (37%); mood improved (26%)"
      },
      "safety": {
        "adverse_events": "Fatigue (12%), appetite change (9%)",
        "serious_adverse_events": "None",
        "dropout_rate": "15%"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Children's Hospital Colorado",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Real-world pediatric data; supported FDA pathway development; Charlotte's Web era",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "EPILEPSY",
      "study_title": "CBD Mechanism of Action in Epilepsy: Multi-Target Effects",
      "citation": "Rosenberg EC, Tsien RW, Bhaskaran M. 2015. Neurotherapeutics; PMID: 26282273; doi: 10.1007/s13311-015-0375-5.",
      "title": "CBD Mechanism of Action in Epilepsy: Multi-Target Effects",
      "authors": "Rosenberg EC, Tsien RW, Bhaskaran M",
      "year": 2015,
      "journal": "Neurotherapeutics",
      "sample_size": "Mechanistic review",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "CBD anticonvulsant mechanisms",
        "results": "Multiple mechanisms: GPR55 antagonism; TRPV1 desensitization; adenosine reuptake inhibition; 5-HT1A agonism; novel target profile",
        "effect_size": "N/A (mechanistic)",
        "secondary_outcomes": "Explains efficacy in drug-resistant epilepsy; non-CB1 mediated; unique pharmacology"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "NIH",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Explains CBD mechanism; supports novel AED classification; scientific rationale",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "EPILEPSY",
      "study_title": "AAN/AES Practice Guideline: Cannabidiol for Treatment-Resistant Epilepsy",
      "citation": "Kanner AM, Ashman E, Gloss D, et al. 2018. Neurology; PMID: 30564780; doi: 10.1002/epi4.12278.",
      "title": "AAN/AES Practice Guideline: Cannabidiol for Treatment-Resistant Epilepsy",
      "authors": "Kanner AM, Ashman E, Gloss D, et al.",
      "year": 2018,
      "journal": "Neurology",
      "sample_size": "Evidence-based guideline",
      "intervention": {
        "cannabinoid": "Pharmaceutical-grade CBD (Epidiolex)",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "AAN/AES guideline recommendations",
        "results": "Level B recommendation for adjunctive CBD in Dravet and LGS; Evidence sufficient for clinical use; Monitoring recommendations provided",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "LFT monitoring required with valproate; dose titration guidance; drug interaction considerations"
      },
      "safety": {
        "adverse_events": "Guideline addresses safety monitoring",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "AAN/AES",
        "conflicts_of_interest": "Managed per AAN policy"
      },
      "regulatory_relevance": "CRITICAL - US neurology society endorsement; shapes clinical practice; supports CBD use",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_RCT_004",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex Second Dravet Trial: Replication Study (GWPCARE2)",
      "citation": "Miller I, Scheffer IE, Gunning B, et al. 2020. JAMA Neurology.",
      "title": "Epidiolex Second Dravet Trial: Replication Study (GWPCARE2)",
      "authors": "Miller I, Scheffer IE, Gunning B, et al.",
      "year": 2020,
      "journal": "JAMA Neurology",
      "sample_size": "199 patients with Dravet syndrome",
      "intervention": {
        "cannabinoid": "Cannabidiol (Epidiolex)",
        "dosage": "10mg/kg/day or 20mg/kg/day",
        "duration": "14 weeks",
        "delivery_method": "Oral solution"
      },
      "outcomes": {
        "primary_measure": "Convulsive seizure frequency",
        "results": "20mg CBD: 45.7% reduction; 10mg CBD: 48.7% reduction; Placebo: 26.9% (p<0.01); Replicates pivotal trial",
        "effect_size": "Large (18-22% vs placebo)",
        "secondary_outcomes": "≥50% responder rate: 44-49% vs 27% placebo; consistent with first trial"
      },
      "safety": {
        "adverse_events": "Somnolence, decreased appetite, diarrhea",
        "serious_adverse_events": "9-14% (elevated LFTs)",
        "dropout_rate": "6.5%"
      },
      "quality_metrics": {
        "randomization": "3-arm parallel",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - Replication strengthens evidence; confirms dose-response; supports labeling",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "EPILEPSY_EPIDEMIOLOGICAL_001",
      "study_type": "EPIDEMIOLOGICAL",
      "condition": "EPILEPSY",
      "study_title": "State Medical Cannabis Laws and Pediatric Epilepsy Treatment Patterns",
      "citation": "Mathern GW, Beninsig L, Nehlig A. 2015. Epilepsia; PMID: 34510448; doi: 10.1111/epi.17021.",
      "title": "State Medical Cannabis Laws and Pediatric Epilepsy Treatment Patterns",
      "authors": "Mathern GW, Beninsig L, Nehlig A",
      "year": 2015,
      "journal": "Epilepsia",
      "sample_size": "N=117,132 pediatric epilepsy cases (HCUP database)",
      "intervention": {
        "cannabinoid": "Medical cannabis access (state-level)",
        "dosage": "N/A",
        "duration": "2002-2013",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "Epilepsy hospitalization rates by state cannabis law status",
        "results": "States with medical cannabis: 13% fewer pediatric epilepsy hospitalizations; Associated with reduced emergency visits",
        "effect_size": "Moderate (13% reduction)",
        "secondary_outcomes": "Suggests population-level benefit; cost reduction implications"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Population health impact; supports state cannabis programs; healthcare utilization data",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CT_NCT04899050",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex in Typical Absence Seizures",
      "citation": "ClinicalTrials.gov NCTNCT04899050",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol (Epidiolex)",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE4",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Amount of epileptiform activity."
        ],
        "outcome_measures": [
          "Amount of epileptiform activity."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04899050",
        "enrollment": 14,
        "phase": "PHASE4",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04899050"
      }
    },
    {
      "study_id": "CT_NCT03467113",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol",
      "citation": "ClinicalTrials.gov NCTNCT03467113",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Adverse Events",
          "Change in Heart Rate",
          "Change in blood pressure",
          "Change in temperature",
          "Change in respiratory rate",
          "Changes in heart rhythm",
          "Changes in heart valve function",
          "Changes in treatment-emergent body weight and height"
        ],
        "outcome_measures": [
          "Adverse Events",
          "Change in Heart Rate",
          "Change in blood pressure",
          "Change in temperature",
          "Change in respiratory rate",
          "Changes in heart rhythm",
          "Changes in heart valve function",
          "Changes in treatment-emergent body weight and height"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03467113",
        "enrollment": 9,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03467113"
      }
    },
    {
      "study_id": "CT_NCT02318602",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder",
      "citation": "ClinicalTrials.gov NCTNCT02318602",
      "publication_year": 2017,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol Oral Solution",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Percentage of Participants With Adverse Events",
          "Percentage of Participants With Serious Adverse Events",
          "Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values",
          "Percentage of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings",
          "Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs",
          "Change From Baseline in Trough Plasma Levels of Cannabidiol and Its 7-OH Metabolite"
        ],
        "outcome_measures": [
          "Percentage of Participants With Adverse Events",
          "Percentage of Participants With Serious Adverse Events",
          "Percentage of Participants With Clinically Significant Change From Baseline in Laboratory Values",
          "Percentage of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings",
          "Percentage of Participants With Clinically Significant Change From Baseline in Vital Signs",
          "Change From Baseline in Trough Plasma Levels of Cannabidiol and Its 7-OH Metabolite"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02318602",
        "enrollment": 52,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02318602"
      }
    },
    {
      "study_id": "CT_NCT02286986",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy",
      "citation": "ClinicalTrials.gov NCTNCT02286986",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Seizure Frequency"
        ],
        "outcome_measures": [
          "Seizure Frequency"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02286986",
        "enrollment": 26,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02286986"
      }
    },
    {
      "study_id": "CT_NCT02700412",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "University of Alabama at Birmingham (UAB) Adult CBD Program",
      "citation": "ClinicalTrials.gov NCTNCT02700412",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Epidiolex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Participants With Severe Adverse Events (SAEs) (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).",
          "Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.",
          "Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant."
        ],
        "outcome_measures": [
          "Number of Participants With Severe Adverse Events (SAEs) (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).",
          "Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.",
          "Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02700412",
        "enrollment": 80,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02700412"
      }
    },
    {
      "study_id": "CT_NCT02332655",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome",
      "citation": "ClinicalTrials.gov NCTNCT02332655",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Seizures Per Month"
        ],
        "outcome_measures": [
          "Number of Seizures Per Month"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02332655",
        "enrollment": 5,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02332655"
      }
    },
    {
      "study_id": "CT_NCT05324449",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Epidiolex® for Anxiety in Pediatric Epilepsy",
      "citation": "ClinicalTrials.gov NCTNCT05324449",
      "publication_year": 2025,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol 100 MG/ML",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE4",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "CGI-I"
        ],
        "outcome_measures": [
          "CGI-I"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05324449",
        "enrollment": 20,
        "phase": "PHASE4",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05324449"
      }
    },
    {
      "study_id": "CT_NCT02695537",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "University of Alabama at Birmingham (UAB) Pediatric CBD Program",
      "citation": "ClinicalTrials.gov NCTNCT02695537",
      "publication_year": 2019,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Epidiolex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).",
          "Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.",
          "Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant."
        ],
        "outcome_measures": [
          "Number of Participants With Severe Adverse Events (Increase in Seizure Frequency by More Than 100% Leading to Emergency Room Visit or Hospitalization).",
          "Number of Participants With Change in Resting Blood Pressure or Heart Rate by 25% if Considered Significant by Managing Neurologist.",
          "Number of Participants With Change in Laboratory Tests Considered by Managing Neurologists as Clinically Significant."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02695537",
        "enrollment": 89,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02695537"
      }
    },
    {
      "study_id": "CT_NCT04280289",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "CBD Cannabis Extract: Pharmacokinetic Studies",
      "citation": "ClinicalTrials.gov NCTNCT04280289",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "cannabidiol extract",
        "delivery_method": "various",
        "dosing_information": "Phase EARLY_PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Plasma concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD).",
          "Urine concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD)."
        ],
        "outcome_measures": [
          "Plasma concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD).",
          "Urine concentration of minor phytocannabinoids, and metabolites following single dose administration of Cannabis extract (CBDE) (at 2.5 mg/kg cannabidiol (CBD)."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04280289",
        "enrollment": 10,
        "phase": "EARLY_PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04280289"
      }
    },
    {
      "study_id": "CT_NCT02324673",
      "study_type": "RCT",
      "condition": "EPILEPSY",
      "study_title": "Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders",
      "citation": "ClinicalTrials.gov NCTNCT02324673",
      "publication_year": 2016,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol Oral Solution",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol",
          "Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age",
          "Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age",
          "Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age",
          "Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age",
          "Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1",
          "Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1",
          "AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1",
          "MRCmax on Day 10",
          "Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age",
          "Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1",
          "Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10",
          "AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10",
          "Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10",
          "Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age",
          "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)",
          "Clinical Global Impression of Improvement (CGI-I) Assessment",
          "Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment",
          "Change From Baseline in Daily Seizure Activity",
          "Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)"
        ],
        "outcome_measures": [
          "Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol",
          "Cmax for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Dose Normalized Cmax (Cmax/D) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Cmax/D for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time to Cmax (Tmax) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Half Life (t1/2) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age",
          "Elimination Rate (Lambda-z [λz]) for Cannabidiol and Metabolite 7-OH Cannabidiol for Participants ≥2 Years of Age",
          "Oral Clearance (CL/F) for Cannabidiol for Participants ≥2 Years of Age",
          "Volume of Distribution (Vz/F) of Cannabidiol for Participants ≥2 Years of Age",
          "Area Under the Plasma-Concentration Time Curve From 0 to 12 Hours Post-dose [AUC(0-12)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1",
          "Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1",
          "AUC From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] on Day 1 for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "AUC From Time 0 to Infinity [AUC(0-inf)] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "Dose Normalized AUC(0-inf) [AUC(0-inf)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 1 for Participants ≥2 Years of Age",
          "Metabolite (7-OH Cannabidiol) to Parent (Cannabidiol) Ratio for Cmax [MRCmax] on Day 1",
          "MRCmax on Day 10",
          "Metabolite to Parent Ratio for AUC(0-inf) [MRAUC(0-inf)] on Day 1 for Participants ≥2 Years of Age",
          "Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 1",
          "Metabolite to Parent Ratio for AUC(0-12) [MRAUC(0-12)] on Day 10",
          "AUC(0-12) for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10",
          "Dose Normalized AUC(0-12) [AUC (0-12)/D] for Cannabidiol and Metabolite 7-OH Cannabidiol on Day 10",
          "Minimum Plasma Concentration (Cmin) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Average Plasma Concentration (Cavg) for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Accumulation Ratio for Cmax (RCmax) on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Accumulation Ratio for AUC(0-12) [RAUC(0-12)] on Day 10 for Cannabidiol and Metabolite 7-OH Cannabidiol",
          "Time Linearity Index for Cannabidiol and Metabolite 7-OH Cannabidiol in Participants ≥2 Years of Age",
          "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)",
          "Clinical Global Impression of Improvement (CGI-I) Assessment",
          "Change From Baseline in Clinical Global Impression of Severity (CGI-S) Assessment",
          "Change From Baseline in Daily Seizure Activity",
          "Number of Participants With Suicide Related Thoughts and Behaviors Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT02324673",
        "enrollment": 61,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT02324673"
      }
    },
    {
      "study_id": "CT_NCT03196466",
      "study_type": "Clinical Trial",
      "condition": "EPILEPSY",
      "study_title": "Population Pharmacokinetics of Antiepileptic in Pediatrics",
      "citation": "ClinicalTrials.gov NCTNCT03196466",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Volume of distribution",
          "Absorption constant",
          "Clearance"
        ],
        "outcome_measures": [
          "Volume of distribution",
          "Absorption constant",
          "Clearance"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03196466",
        "enrollment": 753,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03196466"
      }
    },
    {
      "study_id": "CT_NCT03886753",
      "study_type": "Clinical Trial",
      "condition": "EPILEPSY",
      "study_title": "Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products",
      "citation": "ClinicalTrials.gov NCTNCT03886753",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in symptoms"
        ],
        "outcome_measures": [
          "Change in symptoms"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03886753",
        "enrollment": 10,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03886753"
      }
    }
  ],
  "expansion_metadata": {
    "last_expanded": null,
    "total_expanded": 1
  }
}